Controlled-release galantamine formulations
Controlled-release galantamine formulations, including controlled-release particles, pellets, granules, and spheres are described. Controlled-release particles, pellets, granules, and spheres with immediate release top-coat are also described. Method of preparing such formulations and method of treating a variety of disorders are also disclosed.
1. A controlled-release dosage formulation, comprising:
a core consisting of a core coating layer of 5 wt % to 50 wt % of a water insoluble polymer and 0.1 wt % to 25 wt % of a plastizer, based on the weight of the core coating layer, in admixture with galantamine as the active ingredient, wherein the core coating layer is deposited onto a core substrate to form the core, wherein the core is free of a water soluble excipient; and
a release rate controlling coating substantially surrounding the core, wherein the release rate controlling coating comprises 30 wt % to 90 wt % of a release retarding polymer; and a pore forming excipient comprising a water soluble polymer in an amount of 20:1 to 1:10 release retarding polymer: pore forming excipient; and 0.1 wt % to 30 wt % of a plasticizer,
wherein the formulation exhibits a dissolution profile such that at 1 hour about 4 to about 9% of the galantamine is released, at 2 hours about 15 to about 25% of the galantamine is released, at 4 hours about 40 to about 55% of the galantamine is released, and at 8 hours about 80 to about 100% of the galantamine is released after combining the dosage formulation with 900 ml of pH 6.5 phosphate buffer at 37° C. in USP Type 1 Apparatus (USP, <711> Dissolution), at a paddle speed of 100 rpm.
2. The dosage formulation of claim 1 , wherein the core substrate material is a water insoluble cellulosic polymer, a plastic resin, silica, glass, hydroxyapatite, or activated carbon.
3. The dosage formulation of claim 1 , wherein the water insoluble polymer is a water insoluble cellulosic polymer, a polyvinyl acetate, or a polymethacrylate.
4. The dosage formulation of claim 3 , wherein the water insoluble cellulosic polymer is ethyl cellulose, microcrystalline cellulose, cellulose acetate, cellulose diacetate, cellulose triacetate, or a combination comprising at least one of the foregoing water insoluble celluloses.
5. The dosage formulation of claim 3 , wherein the water insoluble cellulosic polymer is ethyl cellulose.
6. The dosage formulation of claim 1 , wherein the release retarding polymer is a water insoluble cellulosic polymer, a polyvinyl acetate, a polymethacrylate, or a combination comprising at least one of the foregoing release retarding excipients.
7. The dosage formulation of claim 6 , wherein the water insoluble cellulosic polymer is ethyl cellulose, cellulose acetate, cellulose diacetate, cellulose triacetate, or a combination comprising at least one of the foregoing water insoluble cellulosic polymers.
8. The dosage formulation of claim 7 , wherein the water insoluble cellulosic polymer is ethyl cellulose.
9. The dosage formulation of claim 1 , wherein the water soluble polymer is povidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyethylene glycol, or a combination comprising at least one of the foregoing water soluble polymers.
10. The dosage formulation of claim 1 , wherein the release rate controlling coating comprises ethyl cellulose and povidone K30.
11. The dosage formulation of claim 1 , further comprising an immediate release top-coat, wherein the immediate release top-coat comprises a polymer and galantamine.
12. The dosage formulation of claim 11 , wherein the polymer is a water soluble or a water insoluble polymer.
13. The dosage formulation of claim 12 , wherein the water insoluble polymer is ethyl cellulose, cellulose acetate, polyvinyl acetate, a polymethacrylate, or a combination comprising at least one of the foregoing water insoluble polymers.
14. The dosage formulation of claim 12 , wherein the water insoluble polymer is ethyl cellulose.
15. The dosage formulation of claim 12 , wherein the water soluble polymer is an alkyl cellulose; a hydroxyalkyl cellulose; a hydroxyalkyl alkyl cellulose; a carboxyalkyl cellulose; an alkali metal salts of a carboxyalkylcellulose; a carboxyalkyl alkyl cellulose; a carboxyalkyl cellulose ester; a starches; a pectin; a chitine derivate; a polysaccharide; carrageenan; galactomannan; traganth; agar-agar; gummi arabicum;guar gummi; xanthan gummi; a polyacrylic acid; a polymethacrylic acid; a methacrylate copolymer;
a polyvinyl alcohol; a polyvinyl pyrrolidone; a copolymer of polyvinylpyrrolidone with vinyl acetate; a polyalkylene oxide; a copolymer of ethylene oxide and propylene oxide; or a combination comprising at least one of the foregoing water soluble polymers.
16. The dosage formulation of claim 12 , wherein the water soluble polymer is hydroxypropyl methylcellulose.
17. A dosage formulation, comprising:
a core consisting of a core coating layer of 5 wt % to 50 wt % of a water insoluble cellulosic polymer and 0.1 wt % to 25 wt % of a plastizer, based on the weight of the core coating layer, in admixture with galantamine as the active ingredient, wherein the core coating layer is deposited onto a core substrate to form the core, wherein the core is free of a water soluble excipient; and
a release rate controlling coating substantially surrounding the core, wherein the release rate controlling coating comprises 30 wt % to 90 wt % of a water insoluble cellulosic polymer; and a pore forming excipient comprising a water soluble polymer in an amount of 20:1 to 1:10 water insoluble cellulosic polymer: pore forming excipient; and 0.1 wt % to 30 wt % of a plasticizer;
wherein the formulation exhibits a dissolution profile such that at 1 hour about 4 to about 9% of the galantamine is released, at 2 hours about 15 to about 25% of the galantamine is released, at 4 hours about 40 to about 55% of the galantamine is released, and at 8 hours about 80 to about 100% of the galantamine is released after combining the dosage formulation with 900 ml of pH 6.5 phosphate buffer at 37° C. in USP Type 1 Apparatus (USP, <711> Dissolution), at a paddle speed of 100 rpm.
18. The dosage formulation of claim 1 or 11 , wherein the formulation is in the form of tablets, particles, pellets, granules, or spheres,
wherein the particles, pellets, granules, or spheres have a particle size of about 100 to about 2,500 micrometers.
19. A method of treating a disorder selected from dementia, mania, or nicotine dependence in a patient in need thereof comprising administering to the patient the dosage formulation of claim 1 .